AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease

American Gastroenterological Association Institute Clinical Guidelines Committee

doi:10.1053/j.gastro.2021.04.022

AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease

American Gastroenterological Association Institute Clinical Guidelines Committee

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	2496-2508
Number of pages	13
Journal	Gastroenterology
Volume	160
Issue number	7
DOIs	https://doi.org/10.1053/j.gastro.2021.04.022
State	Published - Jun 2021

Bibliographical note

Funding Information:
Conflicts of interest These authors disclose the following: Eugenia Shmidt received research support from Celgene and Takeda . Harminder Singh served on the advisory board of Takeda Canada, Pendopharm, Ferring Merck Canada, and Guardant Health Inc., and also received educational funding from Ferring and research funding from Merck Canada . Harminder Singh also served an advisory role to Guardant Health. Jonathan P. Terdiman received research support from Abbvie. The remaining authors disclose no conflicts. All members were required to complete the disclosure statement. These statements are maintained at the American Gastroenterological Association headquarters in Bethesda, Maryland, and pertinent disclosures are published with this report.

Funding Information:
Conflicts of interest These authors disclose the following: Eugenia Shmidt received research support from Celgene and Takeda. Harminder Singh served on the advisory board of Takeda Canada, Pendopharm, Ferring Merck Canada, and Guardant Health Inc., and also received educational funding from Ferring and research funding from Merck Canada. Harminder Singh also served an advisory role to Guardant Health. Jonathan P. Terdiman received research support from Abbvie. The remaining authors disclose no conflicts. All members were required to complete the disclosure statement. These statements are maintained at the American Gastroenterological Association headquarters in Bethesda, Maryland, and pertinent disclosures are published with this report.

Publisher link

10.1053/j.gastro.2021.04.022

Find It

Find It at U of M Libraries

Cite this

@article{7051e4ddb67b4d1d9c09df44a27043cf,

title = "AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease",

author = "{American Gastroenterological Association Institute Clinical Guidelines Committee} and Feuerstein, {Joseph D.} and Ho, {Edith Y.} and Eugenia Shmidt and Harminder Singh and Yngve Falck-Ytter and Shanaz Sultan and Terdiman, {Jonathan P.} and Shahnaz Sultan and Cohen, {Benjamin L.} and Karen Chachu and Lukejohn Day and Perica Davitkov and Benjamin Lebwohl and Levin, {Theodore R.} and Amit Patel and Peery, {Anne F.} and Raj Shah and Siddharth Singh and Spechler, {Stuart J.} and Kyle Staller and Thrift, {Aaron P.} and Weiss, {Jennifer M.}",

note = "Funding Information: Conflicts of interest These authors disclose the following: Eugenia Shmidt received research support from Celgene and Takeda . Harminder Singh served on the advisory board of Takeda Canada, Pendopharm, Ferring Merck Canada, and Guardant Health Inc., and also received educational funding from Ferring and research funding from Merck Canada . Harminder Singh also served an advisory role to Guardant Health. Jonathan P. Terdiman received research support from Abbvie. The remaining authors disclose no conflicts. All members were required to complete the disclosure statement. These statements are maintained at the American Gastroenterological Association headquarters in Bethesda, Maryland, and pertinent disclosures are published with this report. Funding Information: Conflicts of interest These authors disclose the following: Eugenia Shmidt received research support from Celgene and Takeda. Harminder Singh served on the advisory board of Takeda Canada, Pendopharm, Ferring Merck Canada, and Guardant Health Inc., and also received educational funding from Ferring and research funding from Merck Canada. Harminder Singh also served an advisory role to Guardant Health. Jonathan P. Terdiman received research support from Abbvie. The remaining authors disclose no conflicts. All members were required to complete the disclosure statement. These statements are maintained at the American Gastroenterological Association headquarters in Bethesda, Maryland, and pertinent disclosures are published with this report.",

year = "2021",

month = jun,

doi = "10.1053/j.gastro.2021.04.022",

language = "English (US)",

volume = "160",

pages = "2496--2508",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders",

number = "7",

}

TY - JOUR

T1 - AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease

AU - American Gastroenterological Association Institute Clinical Guidelines Committee

AU - Feuerstein, Joseph D.

AU - Ho, Edith Y.

AU - Shmidt, Eugenia

AU - Singh, Harminder

AU - Falck-Ytter, Yngve

AU - Sultan, Shanaz

AU - Terdiman, Jonathan P.

AU - Sultan, Shahnaz

AU - Cohen, Benjamin L.

AU - Chachu, Karen

AU - Day, Lukejohn

AU - Davitkov, Perica

AU - Lebwohl, Benjamin

AU - Levin, Theodore R.

AU - Patel, Amit

AU - Peery, Anne F.

AU - Shah, Raj

AU - Singh, Siddharth

AU - Spechler, Stuart J.

AU - Staller, Kyle

AU - Thrift, Aaron P.

AU - Weiss, Jennifer M.

N1 - Funding Information: Conflicts of interest These authors disclose the following: Eugenia Shmidt received research support from Celgene and Takeda . Harminder Singh served on the advisory board of Takeda Canada, Pendopharm, Ferring Merck Canada, and Guardant Health Inc., and also received educational funding from Ferring and research funding from Merck Canada . Harminder Singh also served an advisory role to Guardant Health. Jonathan P. Terdiman received research support from Abbvie. The remaining authors disclose no conflicts. All members were required to complete the disclosure statement. These statements are maintained at the American Gastroenterological Association headquarters in Bethesda, Maryland, and pertinent disclosures are published with this report. Funding Information: Conflicts of interest These authors disclose the following: Eugenia Shmidt received research support from Celgene and Takeda. Harminder Singh served on the advisory board of Takeda Canada, Pendopharm, Ferring Merck Canada, and Guardant Health Inc., and also received educational funding from Ferring and research funding from Merck Canada. Harminder Singh also served an advisory role to Guardant Health. Jonathan P. Terdiman received research support from Abbvie. The remaining authors disclose no conflicts. All members were required to complete the disclosure statement. These statements are maintained at the American Gastroenterological Association headquarters in Bethesda, Maryland, and pertinent disclosures are published with this report.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85106495756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106495756&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2021.04.022

DO - 10.1053/j.gastro.2021.04.022

M3 - Article

C2 - 34051983

AN - SCOPUS:85106495756

SN - 0016-5085

VL - 160

SP - 2496

EP - 2508

JO - Gastroenterology

JF - Gastroenterology

IS - 7

ER -

AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease

Bibliographical note

Publisher link

Find It

Other files and links

Cite this